Fortix (formoterol) powder for inhalation caps.12 mcg. №60

Description

Fortix (formoterol) Pharmacological properties

Fortix (formoterol) Pharmacodynamics.

Formoterol fumarate is a selective β2-adrenergic receptor agonist. In patients with reversible airway obstruction, it has a rapid bronchodilating effect (within 1-3 minutes), which persists for 12 hours after inhalation at a high level. In therapeutic doses, the effect on the cardiovascular system is minimal and occurs only in isolated cases. Formoterol inhibits the release of histamine and leukotrienes from the passively sensitized human lung. Some anti-inflammatory effects have been noted, such as a decrease in the severity of edema and inflammatory cell accumulation. Pharmacokinetics. As with other inhaled drugs, about 90% of formoterol, when used with an inhaler, is swallowed and absorbed in the gastrointestinal tract. Therefore, the pharmacokinetic characteristics of formoterol for oral administration can be largely applied to powder for inhalation. Oral doses of formoterol fumarate up to 300 mcg are rapidly absorbed in the gastrointestinal tract. Cmax of unchanged substance in blood plasma is achieved after 0.5-1 hours. The degree of absorption of 80 mcg of the drug taken orally is ≥65%. The pharmacokinetics of formoterol is linear within the studied doses of 20–300 mcg orally. Repeated oral administration of a daily dose of 40–160 mcg does not lead to significant accumulation of the drug in the body. After inhalation administration at therapeutic doses, formoterol cannot be determined in blood plasma using the analytical methods available today. However, the rate of excretion in urine indicates rapid absorption after inhalation. The maximum elimination rate after administration at a dose of 12–96 mcg was achieved in most cases after 1–2 hours.

Fortix (formoterol) Contraindications

Hypersensitivity to formoterol, other components of the drug or other β2-adrenergic receptor agonists. Tachyarrhythmia, 3rd degree atrioventricular block, idiopathic subvalvular aortic stenosis, hypertrophic obstructive cardiomyopathy, thyrotoxicosis. Patients with suspected or established prolongation of the QT interval (QTc> 0.44 s). Children under 6 years of age.

Side effects

From the musculoskeletal system: tremors, muscle spasms, myalgia. From the side of the cardiovascular system: increased heart rate, tachycardia. From the nervous system: headache, agitation, dizziness, anxiety, nervousness, insomnia, anxiety. From the respiratory system: worsening of the clinical condition, dry mouth. Others: irritation of the mucous membrane of the mouth and throat. Special cases: hypersensitivity reactions, such as severe arterial hypotension, rashes, angioedema, itching, peripheral edema, changes in taste, nausea, irritation of the mucous membrane of the eyes, edema of the eyelids.